Department of Pharmacy, UiT The Arctic University of Norway, N-9037 Tromsø, Norway.
Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, England, UK.
Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):124-143. doi: 10.1016/j.bbamcr.2018.09.002. Epub 2018 Sep 8.
It is well established that a family of dual-specificity MAP kinase phosphatases (MKPs) play key roles in the regulated dephosphorylation and inactivation of MAP kinase isoforms in mammalian cells and tissues. MKPs provide a mechanism of spatiotemporal feedback control of these key signalling pathways, but can also mediate crosstalk between distinct MAP kinase cascades and facilitate interactions between MAP kinase pathways and other key signalling modules. As our knowledge of the regulation, substrate specificity and catalytic mechanisms of MKPs has matured, more recent work using genetic models has revealed key physiological functions for MKPs and also uncovered potentially important roles in regulating the pathophysiological outcome of signalling with relevance to human diseases. These include cancer, diabetes, inflammatory and neurodegenerative disorders. It is hoped that this understanding will reveal novel therapeutic targets and biomarkers for disease, thus contributing to more effective diagnosis and treatment for these debilitating and often fatal conditions.
已有充分证据表明,双特异性丝裂原活化蛋白激酶磷酸酶(MKP)家族在调节哺乳动物细胞和组织中 MAP 激酶同工型的去磷酸化和失活方面发挥着关键作用。MKP 为这些关键信号通路的时空反馈控制提供了一种机制,但也可以介导不同 MAP 激酶级联之间的串扰,并促进 MAP 激酶途径与其他关键信号模块之间的相互作用。随着我们对 MKP 的调节、底物特异性和催化机制的认识的成熟,最近使用遗传模型的研究揭示了 MKP 的关键生理功能,并发现了它们在调节与人类疾病相关的信号转导的病理生理结果方面的潜在重要作用。这些疾病包括癌症、糖尿病、炎症和神经退行性疾病。人们希望这种理解将揭示疾病的新的治疗靶点和生物标志物,从而为这些使人衰弱且常常致命的疾病提供更有效的诊断和治疗。